🚀 VC round data is live in beta, check it out!
BRAIN Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for BRAIN Biotech and similar public comparables like Loop Industries, 5E Advanced Materials, Magis, Exel Composites and more.
BRAIN Biotech Overview
About BRAIN Biotech
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
Founded
1993
HQ
Employees
281
Website
Sectors
Financials (LTM)
EV
$66M
BRAIN Biotech Financials
BRAIN Biotech reported last 12-month revenue of $64M and EBITDA of $227K.
In the same LTM period, BRAIN Biotech generated $227K in EBITDA and had net loss of ($9M).
Revenue (LTM)
BRAIN Biotech P&L
In the most recent fiscal year, BRAIN Biotech reported revenue of $62M and EBITDA of ($830K).
BRAIN Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $64M | XXX | $62M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $34M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 54% | XXX | XXX | XXX |
| EBITDA | $227K | XXX | ($830K) | XXX | XXX | XXX |
| EBITDA Margin | 0% | XXX | (1%) | XXX | XXX | XXX |
| EBIT Margin | (9%) | XXX | (11%) | XXX | XXX | XXX |
| Net Profit | ($9M) | XXX | ($11M) | XXX | XXX | XXX |
| Net Margin | (15%) | XXX | (18%) | XXX | XXX | XXX |
| Net Debt | — | — | $741K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BRAIN Biotech Stock Performance
BRAIN Biotech has current market cap of $64M, and enterprise value of $66M.
Market Cap Evolution
BRAIN Biotech's stock price is $2.91.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $66M | $64M | 7.6% | XXX | XXX | XXX | $-0.50 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBRAIN Biotech Valuation Multiples
BRAIN Biotech trades at 1.0x EV/Revenue multiple, and 292.0x EV/EBITDA.
EV / Revenue (LTM)
BRAIN Biotech Financial Valuation Multiples
As of April 18, 2026, BRAIN Biotech has market cap of $64M and EV of $66M.
Equity research analysts estimate BRAIN Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BRAIN Biotech has a P/E ratio of (6.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $64M | XXX | $64M | XXX | XXX | XXX |
| EV (current) | $66M | XXX | $66M | XXX | XXX | XXX |
| EV/Revenue | 1.0x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | 292.0x | XXX | (79.7x) | XXX | XXX | XXX |
| EV/EBIT | (12.1x) | XXX | (9.4x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 2.0x | XXX | XXX | XXX |
| P/E | (6.8x) | XXX | (5.8x) | XXX | XXX | XXX |
| EV/FCF | (8.9x) | XXX | (5.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BRAIN Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
BRAIN Biotech Margins & Growth Rates
BRAIN Biotech's revenue in the last 12 month grew by 14%.
BRAIN Biotech's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
BRAIN Biotech's rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BRAIN Biotech's rule of X is 39% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
BRAIN Biotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 0% | XXX | (1%) | XXX | XXX | XXX |
| EBITDA Growth | 2209% | XXX | (232%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 18% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 39% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 69% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
BRAIN Biotech Public Comps
See public comps and valuation multiples for other Chemicals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| BRAIN Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Loop Industries | XXX | XXX | XXX | XXX | XXX | XXX |
| 5E Advanced Materials | XXX | XXX | XXX | XXX | XXX | XXX |
| Magis | XXX | XXX | XXX | XXX | XXX | XXX |
| Exel Composites | XXX | XXX | XXX | XXX | XXX | XXX |
| Enka de Colombia | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BRAIN Biotech M&A Activity
BRAIN Biotech acquired XXX companies to date.
Last acquisition by BRAIN Biotech was on XXXXXXXX, XXXXX. BRAIN Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by BRAIN Biotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBRAIN Biotech Investment Activity
BRAIN Biotech invested in XXX companies to date.
BRAIN Biotech made its latest investment on XXXXXXXX, XXXXX. BRAIN Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by BRAIN Biotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BRAIN Biotech
| When was BRAIN Biotech founded? | BRAIN Biotech was founded in 1993. |
| Where is BRAIN Biotech headquartered? | BRAIN Biotech is headquartered in Germany. |
| How many employees does BRAIN Biotech have? | As of today, BRAIN Biotech has over 281 employees. |
| Is BRAIN Biotech publicly listed? | Yes, BRAIN Biotech is a public company listed on Frankfurt Stock Exchange. |
| What is the stock symbol of BRAIN Biotech? | BRAIN Biotech trades under BNN ticker. |
| When did BRAIN Biotech go public? | BRAIN Biotech went public in 2016. |
| Who are competitors of BRAIN Biotech? | BRAIN Biotech main competitors are Loop Industries, 5E Advanced Materials, Magis, Exel Composites. |
| What is the current market cap of BRAIN Biotech? | BRAIN Biotech's current market cap is $64M. |
| What is the current revenue of BRAIN Biotech? | BRAIN Biotech's last 12 months revenue is $64M. |
| What is the current revenue growth of BRAIN Biotech? | BRAIN Biotech revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of BRAIN Biotech? | Current revenue multiple of BRAIN Biotech is 1.0x. |
| Is BRAIN Biotech profitable? | Yes, BRAIN Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BRAIN Biotech? | BRAIN Biotech's last 12 months EBITDA is $227K. |
| What is BRAIN Biotech's EBITDA margin? | BRAIN Biotech's last 12 months EBITDA margin is 0%. |
| What is the current EV/EBITDA multiple of BRAIN Biotech? | Current EBITDA multiple of BRAIN Biotech is 292.0x. |
| What is the current FCF of BRAIN Biotech? | BRAIN Biotech's last 12 months FCF is ($7M). |
| What is BRAIN Biotech's FCF margin? | BRAIN Biotech's last 12 months FCF margin is (12%). |
| What is the current EV/FCF multiple of BRAIN Biotech? | Current FCF multiple of BRAIN Biotech is (8.9x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.